🇺🇸 KTE-X19 in United States

179 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 179

Most-reported reactions

1. Cytokine Release Syndrome — 54 reports (30.17%)
2. Hypotension — 26 reports (14.53%)
3. Pyrexia — 25 reports (13.97%)
4. Immune Effector Cell-Associated Neurotoxicity Syndrome — 21 reports (11.73%)
5. Encephalopathy — 11 reports (6.15%)
6. Hypoxia — 11 reports (6.15%)
7. Sepsis — 9 reports (5.03%)
8. Confusional State — 8 reports (4.47%)
9. Neurotoxicity — 8 reports (4.47%)
10. Aphasia — 6 reports (3.35%)

Source database →

Frequently asked questions

Is KTE-X19 approved in United States?

KTE-X19 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for KTE-X19 in United States?

Kite, A Gilead Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.